Signs and symptoms of infusion-related reactions may include1
- Chills or shaking
- Itching or rash
- Flushing
- Shortness of breath
- Dizziness
- Feel like passing out
- Fever
- Back or neck pain
Management considerations for infusion-related reactions for Opdualag1
- Opdualag can cause severe infusion-related reactions
- Mild or moderate symptoms (Grade 1 or 2)*: Interrupt or slow the rate of infusion
- Severe or life-threatening symptoms (Grade 3 or 4)*: Permanently discontinue treatment
*In a trial that evaluated Opdualag, toxicity was graded per NCI CTCAE V5.0.1
NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.
Select Important Safety Information
Infusion-Related Reactions
Opdualag can cause severe infusion-related reactions. Discontinue Opdualag in patients with severe or life-threatening infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild to moderate infusion-related reactions. In patients who received Opdualag as a 60-minute intravenous infusion, infusion-related reactions occurred in 7% (23/355) of patients.
Dosing Schedule
Learn more about the dosing schedule for this fixed-dose combination therapy.
Patient Monitoring
Checklist
A convenient, printable tool to help nurses identify signs and symptoms of immune-mediated adverse reactions.
Reference:
- Opdualag [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.